Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype

Purpose: To investigate the proportion of breast cancers arising in patients with germ line BRCA1 and BRCA2 mutations expressing basal markers and developing predictive tests for identification of high-risk patients. Experimental Design: Histopathologic material from 182 tumors in BRCA1 mutation carriers, 63 BRCA2 carriers, and 109 controls, collected as part of the international Breast Cancer Linkage Consortium were immunohistochemically stained for CK14, CK5/6, CK17, epidermal growth factor receptor (EGFR), and osteonectin. Results: All five basal markers were commoner in BRCA1 tumors than in control tumors (CK14: 61% versus 12%; CK5/6: 58% versus 7%; CK17: 53% versus 10%; osteonectin: 43% versus 19%; EGFR: 67% versus 21%; P < 0.0001 in each case). In a multivariate analysis, CK14, CK5/6, and estrogen receptor (ER) remained significant predictors of BRCA1 carrier status. In contrast, the frequency of basal markers in BRCA2 tumors did not differ significant from controls. Conclusion: The use of cytokeratin staining in combination with ER and morphology provides a more accurate predictor of BRCA1 mutation status than previously available, that may be useful in selecting patients for BRCA1 mutation testing. The high percentage of BRCA1 cases positive for EGFR suggests that specific anti-tyrosine kinase therapy may be of potential benefit in these patients.

[1]  B. Ljung,et al.  Immunolocalization of a human basal epithelium specific keratin in benign and malignant breast disease , 1987, Breast Cancer Research and Treatment.

[2]  Jorge S. Reis-Filho,et al.  Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes , 2004, Clinical Cancer Research.

[3]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[4]  Alan Mackay,et al.  Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. , 2004, Cancer research.

[5]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[6]  H. Cortés-Funes,et al.  Extensive experience of disease control with gefitinib and the role of prognostic markers , 2003, British Journal of Cancer.

[7]  J. Satagopan,et al.  A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.

[8]  W. Boecker,et al.  Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept , 2003, Cell proliferation.

[9]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Tibshirani,et al.  Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .

[12]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Santini,et al.  Immunocytochemical Expression of Epidermal Growth Factor Receptor in Myoepithelial Cells of the Breast , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[14]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Lakhani,et al.  CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation , 2001, British Journal of Cancer.

[16]  D. Visscher,et al.  Centrally Necrotizing Carcinomas of the Breast: A Distinct Histologic Subtype With Aggressive Clinical Behavior , 2001, The American journal of surgical pathology.

[17]  J. Sudbø,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[18]  A. Vincent-Salomon,et al.  Familial invasive breast cancers: worse outcome related to BRCA1 mutations. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[20]  L. Bégin,et al.  Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  M. Stratton,et al.  The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  S. Hirohashi,et al.  Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. , 2000, The American journal of surgical pathology.

[23]  S. Hirohashi,et al.  Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones. , 1999, Human pathology.

[24]  S. Seal,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[25]  Nazneen,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[26]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[27]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.

[28]  M. Stratton.  Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.

[29]  P. Maxwell,et al.  Cytokeratin intermediate filament expression in benign and malignant breast disease. , 1995, Journal of clinical pathology.

[30]  B. Gusterson,et al.  Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases. , 1982, Cancer research.